Literature DB >> 9402351

Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University.

A Ramirez-Ramos1, R H Gilman, R Leon-Barua, S Recavarren-Arce, J Watanabe, G Salazar, W Checkley, J McDonald, Y Valdez, L Cordero, J Carrazco.   

Abstract

Helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer. Since gastric cancer is common in Peru, eradication of H. pylori may help to reduce the occurrence of gastric cancer. This study involved three randomized trials to determine the efficacy of four different triple-drug therapy regimens. The most successful regimen was furazolidone combined with bismuth subsalicylate and amoxicillin, which eradicated infection in 82% of patients. Patients successfully treated were followed every 2-3 months to determine the recurrence rate of H. pylori infection. Of 105 patients with H. pylori eradication documented by pathology and culture, 52% (55) returned for follow-up endoscopy, and in 73% (40) of these 55 the infection recurred during the 8-month follow-up period. Thirty-five patients from whom H. pylori was eradicated and who were tested for antibodies to H. pylori remained consistently seropositive. Rapid recurrence of H. pylori infection after successful eradication suggests that measures other than antimicrobial therapy are needed to fight H. pylori in developing countries.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9402351     DOI: 10.1086/516083

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

1.  Helicobacter pylori-associated chronic atrophic gastritis involving the gastric body and severe disease by Vibrio cholerae.

Authors:  Raúl León-Barúa; Sixto Recavarren-Arce; Erick Chinga-Alayo; Carlos Rodríguez-Ulloa; David N Taylor; Eduardo Gotuzzo; Margaret Kosek; Dominique Eza; Robert H Gilman
Journal:  Trans R Soc Trop Med Hyg       Date:  2005-12-22       Impact factor: 2.184

2.  Human lactoferrin increases Helicobacter pylori internalisation into AGS cells.

Authors:  Dorien S Coray; Jack A Heinemann; Peter C Tyrer; Jacqueline I Keenan
Journal:  World J Microbiol Biotechnol       Date:  2012-02-07       Impact factor: 3.312

3.  Peptide Extracts from Cultures of Certain Lactobacilli Inhibit Helicobacter pylori.

Authors:  Luc De Vuyst; Pascal Vincent; Eleftherios Makras; Frédéric Leroy; Bruno Pot
Journal:  Probiotics Antimicrob Proteins       Date:  2010-03       Impact factor: 4.609

Review 4.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 5.  Optimal therapy for Helicobacter pylori infections.

Authors:  Emiko Rimbara; Lori A Fischbach; David Y Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

6.  Posttreatment follow-up of Helicobacter pylori infection using a stool antigen immunoassay.

Authors:  D E Roth; D N Taylor; R H Gilman; R Meza; U Katz; C Bautista; L Cabrera; B Velapatiño; C Lebron; M Razúri; J Watanabe; T Monath
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

7.  Antimicrobial susceptibility of Helicobacter pylori determined by the E test using tetrazolium egg yolk agar.

Authors:  Y Valdez; B Velapatiño; R H Gilman; V Gutierrez; C León
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

8.  Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen.

Authors:  Patricia Londoño-Arcila; Donna Freeman; Harry Kleanthous; Aisling M O'Dowd; Susan Lewis; Arthur K Turner; Emma L Rees; Timothy J Tibbitts; Judith Greenwood; Thomas P Monath; Michael J Darsley
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

9.  Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers.

Authors:  S Banerjee; A Medina-Fatimi; R Nichols; D Tendler; M Michetti; J Simon; C P Kelly; T P Monath; P Michetti
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

10.  Reinfection Rate after Successful Helicobacter pylori Eradication in Children.

Authors:  Mehri Najafi; Mohammad Sobhani; Ahmad Khodadad; Fatemeh Farahmand; Farzaneh Motamed
Journal:  Iran J Pediatr       Date:  2010-03       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.